-

CASSAVA SCIENCES SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVA

NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 10, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cassava Sciences, Inc. (NasdaqCM: SAVA), if they purchased the Company’s securities between February 7, 2024 and November 24, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the Western District of Texas.

What You May Do

If you purchased securities of Cassava and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqcm-sava/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by February 10, 2025.

About the Lawsuit

Cassava and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On November 25, 2024, the Company disclosed topline results for the first of its two ongoing Phase 3 studies on its leading drug candidate, simufilam, the “ReThink-ALZ” study, that indicated that simufilam failed to meet each of the pre-specified primary, secondary, and exploratory endpoints; in sum, simufilam failed to outperform the placebo.

On this news, the price of Cassava’s shares fell approximately 83%, from a closing price of $26.48 per share on November 22, 2024, to $4.30 per share on November 25, 2024.

The case is Crocker v. Cassava Sciences, Inc., et al., No. 24-cv-1525.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Chicago, Louisiana and New Jersey.

To learn more about KSF, you may visit www.ksfcounsel.com.

Contacts

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163

Industry:

Kahn Swick & Foti, LLC

NASDAQ:SAVA
Release Versions
English

Contacts

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850
1100 Poydras St., Suite 960
New Orleans, LA 70163

More News From Kahn Swick & Foti, LLC

CarMax Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of CarMax, Inc. - KMX

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into CarMax, Inc. (NYSE: KMX) (“CarMax” or the “Company”).On September 25, 2025, the Company announced its second quarter Fiscal Year 2026 financial results, disclosing, among other things, that retail unit sales had decreased 5.4%, comparable store unit sales had decreased 6.3...

Equitable Holdings Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Equitable Holdings, Inc. - EQH

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Equitable Holdings, Inc. (NYSE: EQH) and Corebridge Financial, Inc. (NYSE: CRBG). Under the terms of the agreement, each outstanding share of Equitable common stock will be exchanged for the right to receive 1.55516 shares of the new parent company’s common stock, and upon completion of the proposed transact...

Day One Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Day One Biopharmaceuticals, Inc. - DAWN

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Day One Biopharmaceuticals, Inc. (NasdaqGS: DAWN) to Servier. Under the terms of the proposed transaction, shareholders of Day One will receive $21.50 in cash for each share of Day One that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate,...
Back to Newsroom